Key result
PAS-C and dietary therapy lower plasma cholesterol by ~23% versus placebo.
Why the study?
Does para-aminosalicylic acid combined with dietary therapy reduce serum lipids in patients with Types IIa and IIb hyperlipoproteinemia?
RCT (n=63)
Single-blind
Does para-aminosalicylic acid combined with dietary therapy reduce serum lipids in patients with Types IIa and IIb hyperlipoproteinemia?
Para-aminosalicylic acid combined with dietary therapy provides significant and sustained reductions in cholesterol, triglycerides, and LDL-cholesterol in patients with hyperlipoproteinemia.
Answers are grounded in this paper and cite their sources.
PAS-C-diet may lower lipids in type II hyperlipoproteinemia; leaves open its role versus contemporary therapies.
The hypolipidemic effect of PAS-C-diet treatment was studied in 63 patients with Types IIa and IIb hyperlipoproteinemia for 6-36 months. Serum lipids and body weights of all patients were stabilized by a low cholesterol-saturated fat-refined carbohydrate diet before the initiation of an eight-week placebo-drug single-blind crossover study. During the placebo period the plasma lipids levels, mean +/- SD: cholesterol 355 +/- 63.5 mg%, triglyceride 141 +/- 68.7 mg%, and LDL-cholesterol 279 +/- 56.8 mg% were lowered to 274 +/- 53.1 mg+, 98 +/- 40.6 mg%, and 209 +/- 52.9 mg%, respectively (P less than 0.001 in each instance), with 7.5-11.0 grams of PAS-C/day given in one to three divided doses. In ten patients who have completed three years of treatment similar results were obtained. They showed no tendency to develop drug tolerance. Eight had watery diarrhea during the initial period which promptly subsided with interruption of drug therapy. Reintroduction of PAS-C in smaller dose (4.5 g/day) with gradual increment to effective dosage level was tolerated by all. No hematologic, hepatic, and ophthalmologic abnormalities were demonstrated by periodic monitoring. The hypoplipidemic effect of the drug was found to be diminished by alcohol and caloric excess.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (1976) conducted an RCT in Types IIa and IIb hyperlipoproteinemia (n=63). para-aminosalicylic acid (PAS-C) and dietary therapy vs. Placebo was evaluated on plasma cholesterol level (mg%) (p=<0.001). Treatment with PAS-C and dietary therapy significantly lowered plasma cholesterol to 274 mg% compared to 355 mg% during the placebo period (P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: